{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T10:24:19Z","timestamp":1789986259500,"version":"4.0.1"},"reference-count":55,"publisher":"MDPI AG","issue":"14","license":[{"start":{"date-parts":[[2025,7,9]],"date-time":"2025-07-09T00:00:00Z","timestamp":1752019200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100000780","name":"The European Union\u2019s Horizon Europe research and innovation program","doi-asserted-by":"publisher","award":["101136957"],"award-info":[{"award-number":["101136957"]}],"id":[{"id":"10.13039\/501100000780","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000780","name":"The European Union\u2019s Horizon Europe research and innovation program","doi-asserted-by":"publisher","award":["101132356"],"award-info":[{"award-number":["101132356"]}],"id":[{"id":"10.13039\/501100000780","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000780","name":"The European Union\u2019s Horizon Europe research and innovation program","doi-asserted-by":"publisher","award":["JPND2023-1822-085"],"award-info":[{"award-number":["JPND2023-1822-085"]}],"id":[{"id":"10.13039\/501100000780","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000780","name":"The European Union\u2019s Horizon Europe research and innovation program","doi-asserted-by":"publisher","award":["2024-1.2.2-ERA_NET-2024-00013"],"award-info":[{"award-number":["2024-1.2.2-ERA_NET-2024-00013"]}],"id":[{"id":"10.13039\/501100000780","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000780","name":"The European Union\u2019s Horizon Europe research and innovation program","doi-asserted-by":"publisher","award":["2020-1.1.2-PIACI-KFI-2021-00233"],"award-info":[{"award-number":["2020-1.1.2-PIACI-KFI-2021-00233"]}],"id":[{"id":"10.13039\/501100000780","id-type":"DOI","asserted-by":"publisher"}]},{"name":"The Innovative Health Initiative Joint Undertaking","award":["101136957"],"award-info":[{"award-number":["101136957"]}]},{"name":"The Innovative Health Initiative Joint Undertaking","award":["101132356"],"award-info":[{"award-number":["101132356"]}]},{"name":"The Innovative Health Initiative Joint Undertaking","award":["JPND2023-1822-085"],"award-info":[{"award-number":["JPND2023-1822-085"]}]},{"name":"The Innovative Health Initiative Joint Undertaking","award":["2024-1.2.2-ERA_NET-2024-00013"],"award-info":[{"award-number":["2024-1.2.2-ERA_NET-2024-00013"]}]},{"name":"The Innovative Health Initiative Joint Undertaking","award":["2020-1.1.2-PIACI-KFI-2021-00233"],"award-info":[{"award-number":["2020-1.1.2-PIACI-KFI-2021-00233"]}]},{"name":"European Union\u2019s Horizon Europe research and innovation program, COCIR, EFPIA, EuropaBio, MedTechEurope, and Vaccines Europe","award":["101136957"],"award-info":[{"award-number":["101136957"]}]},{"name":"European Union\u2019s Horizon Europe research and innovation program, COCIR, EFPIA, EuropaBio, MedTechEurope, and Vaccines Europe","award":["101132356"],"award-info":[{"award-number":["101132356"]}]},{"name":"European Union\u2019s Horizon Europe research and innovation program, COCIR, EFPIA, EuropaBio, MedTechEurope, and Vaccines Europe","award":["JPND2023-1822-085"],"award-info":[{"award-number":["JPND2023-1822-085"]}]},{"name":"European Union\u2019s Horizon Europe research and innovation program, COCIR, EFPIA, EuropaBio, MedTechEurope, and Vaccines Europe","award":["2024-1.2.2-ERA_NET-2024-00013"],"award-info":[{"award-number":["2024-1.2.2-ERA_NET-2024-00013"]}]},{"name":"European Union\u2019s Horizon Europe research and innovation program, COCIR, EFPIA, EuropaBio, MedTechEurope, and Vaccines Europe","award":["2020-1.1.2-PIACI-KFI-2021-00233"],"award-info":[{"award-number":["2020-1.1.2-PIACI-KFI-2021-00233"]}]},{"name":"The EU Joint Programme\u2014Neurodegenerative Disease Research","award":["101136957"],"award-info":[{"award-number":["101136957"]}]},{"name":"The EU Joint Programme\u2014Neurodegenerative Disease Research","award":["101132356"],"award-info":[{"award-number":["101132356"]}]},{"name":"The EU Joint Programme\u2014Neurodegenerative Disease Research","award":["JPND2023-1822-085"],"award-info":[{"award-number":["JPND2023-1822-085"]}]},{"name":"The EU Joint Programme\u2014Neurodegenerative Disease Research","award":["2024-1.2.2-ERA_NET-2024-00013"],"award-info":[{"award-number":["2024-1.2.2-ERA_NET-2024-00013"]}]},{"name":"The EU Joint Programme\u2014Neurodegenerative Disease Research","award":["2020-1.1.2-PIACI-KFI-2021-00233"],"award-info":[{"award-number":["2020-1.1.2-PIACI-KFI-2021-00233"]}]},{"DOI":"10.13039\/501100003827","name":"The National Research Development and Innovation Office, Hungary","doi-asserted-by":"publisher","award":["101136957"],"award-info":[{"award-number":["101136957"]}],"id":[{"id":"10.13039\/501100003827","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003827","name":"The National Research Development and Innovation Office, Hungary","doi-asserted-by":"publisher","award":["101132356"],"award-info":[{"award-number":["101132356"]}],"id":[{"id":"10.13039\/501100003827","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003827","name":"The National Research Development and Innovation Office, Hungary","doi-asserted-by":"publisher","award":["JPND2023-1822-085"],"award-info":[{"award-number":["JPND2023-1822-085"]}],"id":[{"id":"10.13039\/501100003827","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003827","name":"The National Research Development and Innovation Office, Hungary","doi-asserted-by":"publisher","award":["2024-1.2.2-ERA_NET-2024-00013"],"award-info":[{"award-number":["2024-1.2.2-ERA_NET-2024-00013"]}],"id":[{"id":"10.13039\/501100003827","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003827","name":"The National Research Development and Innovation Office, Hungary","doi-asserted-by":"publisher","award":["2020-1.1.2-PIACI-KFI-2021-00233"],"award-info":[{"award-number":["2020-1.1.2-PIACI-KFI-2021-00233"]}],"id":[{"id":"10.13039\/501100003827","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>Syndecan-3 (SDC3), a transmembrane heparan sulfate proteoglycan involved in cell signaling and endocytosis, has recently been implicated in the pathogenesis of neurodegenerative disorders. While preclinical studies have demonstrated its role in Alzheimer\u2019s disease (AD), its diagnostic relevance in peripheral blood remains unexplored. In this human cohort study, we measured SDC3 expression in peripheral blood mononuclear cells (PBMCs) from 22 clinically diagnosed AD patients and 20 cognitively unimpaired non-AD controls using a custom ELISA. The findings were compared with plasma p-tau217 levels and a panel of systemic laboratory markers. PBMC-expressed SDC3 was significantly elevated in AD patients and moderately correlated with AD status (r = 0.309, p = 0.0465) independent of age. Notably, SDC3 levels were inversely correlated with systemic inflammatory markers, including C-reactive protein (CRP; r = \u22120.421, p = 0.0055) and D-dimer (r = \u22120.343, p = 0.038), suggesting an AD-associated immune phenotype distinct from acute-phase or vascular inflammation. Conversely, plasma p-tau217 levels did not significantly differ between groups but correlated with markers of tissue injury and inflammation (LDH, GOT, and ferritin), potentially reflecting systemic influences in non-AD controls. A multivariable logistic regression model incorporating SDC3, p-tau217, and age demonstrated high diagnostic accuracy (AUC = 0.85). These findings identify PBMC-expressed SDC3 as a promising blood-based biomarker candidate for AD, warranting further validation in larger, biomarker-confirmed cohorts.<\/jats:p>","DOI":"10.3390\/ijms26146587","type":"journal-article","created":{"date-parts":[[2025,7,11]],"date-time":"2025-07-11T12:46:33Z","timestamp":1752237993000},"page":"6587","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Peripheral Leukocyte Syndecan-3 Is Elevated in Alzheimer\u2019s Disease: Evidence from a Human Study"],"prefix":"10.3390","volume":"26","author":[{"ORCID":"https:\/\/orcid.org\/0009-0009-6294-5345","authenticated-orcid":false,"given":"Anett","family":"Hud\u00e1k","sequence":"first","affiliation":[{"name":"Pharmacoidea Ltd., H-6726 Szeged, Hungary"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annam\u00e1ria","family":"Letoha","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Albert Szent-Gy\u00f6rgyi Clinical Center, Faculty of Medicine, University of Szeged, H-6720 Szeged, Hungary"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6035-4009","authenticated-orcid":false,"given":"Tam\u00e1s","family":"Letoha","sequence":"additional","affiliation":[{"name":"Pharmacoidea Ltd., H-6726 Szeged, Hungary"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2025,7,9]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"102481","DOI":"10.1016\/j.arr.2024.102481","article-title":"Pathogenesis, diagnostics, and therapeutics for Alzheimer\u2019s disease: Breaking the memory barrier","volume":"101","author":"Kamatham","year":"2024","journal-title":"Ageing Res. Rev."},{"key":"ref_2","doi-asserted-by":"crossref","unstructured":"(2024). 2024 Alzheimer\u2019s disease facts and figures. Alzheimers Dement., 20, 3708\u20133821.","DOI":"10.1002\/alz.13809"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1038\/s41392-024-01911-3","article-title":"Recent advances in Alzheimer\u2019s disease: Mechanisms, clinical trials and new drug development strategies","volume":"9","author":"Zhang","year":"2024","journal-title":"Signal Transduct. Target. Ther."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"100078","DOI":"10.1016\/j.neumar.2025.100078","article-title":"Blood biomarkers for clinical applications in Alzheimer\u2019s disease: A narrative review","volume":"2","author":"Li","year":"2025","journal-title":"NeuroMarkers"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"21","DOI":"10.3233\/ADR-190143","article-title":"Role of Fluid Biomarkers and PET Imaging in Early Diagnosis and its Clinical Implication in the Management of Alzheimer\u2019s Disease","volume":"4","author":"Hameed","year":"2020","journal-title":"J. Alzheimers Dis. Rep."},{"key":"ref_6","doi-asserted-by":"crossref","unstructured":"Varesi, A., Carrara, A., Pires, V.G., Floris, V., Pierella, E., Savioli, G., Prasad, S., Esposito, C., Ricevuti, G., and Chirumbolo, S. (2022). Blood-Based Biomarkers for Alzheimer\u2019s Disease Diagnosis and Progression: An Overview. Cells, 11.","DOI":"10.3390\/cells11081367"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"100630","DOI":"10.1016\/j.lanhl.2024.07.013","article-title":"Challenges in the practical implementation of blood biomarkers for Alzheimer\u2019s disease","volume":"5","author":"Verberk","year":"2024","journal-title":"Lancet Healthy Longev."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"e14482","DOI":"10.1002\/alz.14482","article-title":"Plasma p-tau(217) and neurofilament\/p-tau(217) ratio in differentiating Alzheimer\u2019s disease from syndromes associated with frontotemporal lobar degeneration","volume":"21","author":"Benussi","year":"2025","journal-title":"Alzheimers Dement."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1007\/s11011-022-01114-1","article-title":"Blood-based biomarkers in Alzheimer\u2019s disease: A mini-review","volume":"38","author":"Padala","year":"2023","journal-title":"Metab. Brain Dis."},{"key":"ref_10","doi-asserted-by":"crossref","unstructured":"Lai, R., Li, B., and Bishnoi, R. (2024). P-tau217 as a Reliable Blood-Based Marker of Alzheimer\u2019s Disease. Biomedicines, 12.","DOI":"10.3390\/biomedicines12081836"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"658","DOI":"10.14336\/AD.2024.0286","article-title":"Amyloid-beta and Phosphorylated Tau are the Key Biomarkers and Predictors of Alzheimer\u2019s Disease","volume":"16","author":"Pradeepkiran","year":"2024","journal-title":"Aging Dis."},{"key":"ref_12","first-page":"26","article-title":"Advances in biomarkers for Alzheimer\u2019s disease and vascular cognitive impairment and dementia: Current status and clinical implications","volume":"11","author":"Hosoki","year":"2025","journal-title":"Vas-Cog J."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1038\/s41582-021-00549-x","article-title":"Peripheral and central immune system crosstalk in Alzheimer disease\u2014A research prospectus","volume":"17","author":"Bettcher","year":"2021","journal-title":"Nat. Rev. Neurol."},{"key":"ref_14","doi-asserted-by":"crossref","unstructured":"Hudak, A., Kusz, E., Domonkos, I., Josvay, K., Kodamullil, A.T., Szilak, L., Hofmann-Apitius, M., and Letoha, T. (2019). Contribution of syndecans to cellular uptake and fibrillation of alpha-synuclein and tau. Sci. Rep., 9.","DOI":"10.1038\/s41598-019-53038-z"},{"key":"ref_15","doi-asserted-by":"crossref","unstructured":"Letoha, T., Hudak, A., Kusz, E., Pettko-Szandtner, A., Domonkos, I., Josvay, K., Hofmann-Apitius, M., and Szilak, L. (2019). Contribution of syndecans to cellular internalization and fibrillation of amyloid-beta(1\u201342). Sci. Rep., 9.","DOI":"10.1038\/s41598-018-37476-9"},{"key":"ref_16","doi-asserted-by":"crossref","unstructured":"Hudak, A., Letoha, A., Vizler, C., and Letoha, T. (2022). Syndecan-3 as a Novel Biomarker in Alzheimer\u2019s Disease. Int. J. Mol. Sci., 23.","DOI":"10.3390\/ijms23063407"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1083\/jcb.201009136","article-title":"Heparan sulfate proteoglycan syndecan-3 is a novel receptor for GDNF, neurturin, and artemin","volume":"192","author":"Bespalov","year":"2011","journal-title":"J. Cell Biol."},{"key":"ref_18","doi-asserted-by":"crossref","unstructured":"Hudak, A., Josvay, K., Domonkos, I., Letoha, A., Szilak, L., and Letoha, T. (2021). The Interplay of Apoes with Syndecans in Influencing Key Cellular Events of Amyloid Pathology. Int. J. Mol. Sci., 22.","DOI":"10.3390\/ijms22137070"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"332ra344","DOI":"10.1126\/scitranslmed.aad3650","article-title":"Neuronal heparan sulfates promote amyloid pathology by modulating brain amyloid-beta clearance and aggregation in Alzheimer\u2019s disease","volume":"8","author":"Liu","year":"2016","journal-title":"Sci. Transl. Med."},{"key":"ref_20","first-page":"2755","article-title":"Molecular properties underlying regional vulnerability to Alzheimer\u2019s disease pathology","volume":"141","author":"Grothe","year":"2018","journal-title":"Brain"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1186\/s12979-024-00445-0","article-title":"Neuroinflammation in Alzheimer\u2019s disease: Insights from peripheral immune cells","volume":"21","author":"Zhang","year":"2024","journal-title":"Immun. Ageing"},{"key":"ref_22","doi-asserted-by":"crossref","unstructured":"Morales, I., Guzman-Martinez, L., Cerda-Troncoso, C., Farias, G.A., and Maccioni, R.B. (2014). Neuroinflammation in the pathogenesis of Alzheimer\u2019s disease. A rational framework for the search of novel therapeutic approaches. Front. Cell Neurosci., 8.","DOI":"10.3389\/fncel.2014.00112"},{"key":"ref_23","first-page":"575","article-title":"Inflammation as a central mechanism in Alzheimer\u2019s disease","volume":"4","author":"Kinney","year":"2018","journal-title":"Alzheimers Dement."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1016\/j.jalz.2018.02.018","article-title":"NIA-AA Research Framework: Toward a biological definition of Alzheimer\u2019s disease","volume":"14","author":"Jack","year":"2018","journal-title":"Alzheimers Dement."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1038\/s41392-023-01451-2","article-title":"Immunosenescence: Molecular mechanisms and diseases","volume":"8","author":"Liu","year":"2023","journal-title":"Signal Transduct. Target. Ther."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1186\/2046-2395-1-8","article-title":"Immunosenescence, inflammation and Alzheimer\u2019s disease","volume":"1","author":"Martorana","year":"2012","journal-title":"Longev. Heal."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"715","DOI":"10.14283\/jpad.2022.77","article-title":"Antihypertensive Agents and Incident Alzheimer\u2019s Disease: A Systematic Review and Meta-Analysis of Observational Studies","volume":"9","author":"Adesuyan","year":"2022","journal-title":"J. Prev. Alzheimers Dis."},{"key":"ref_28","first-page":"e12060","article-title":"Antihypertensive medications ameliorate Alzheimer\u2019s disease pathology by slowing its propagation","volume":"6","author":"Affleck","year":"2020","journal-title":"Alzheimers Dement."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.3233\/JAD-150831","article-title":"Effects of Hypertension and Anti-Hypertensive Treatment on Amyloid-beta (Abeta) Plaque Load and Abeta-Synthesizing and Abeta-Degrading Enzymes in Frontal Cortex","volume":"50","author":"Ashby","year":"2016","journal-title":"J. Alzheimers Dis."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1253\/circj.CJ-12-1550","article-title":"Angiotensin-receptor blockers, hypertension and Alzheimer disease\u2014The entangled relationship","volume":"77","author":"Katayama","year":"2013","journal-title":"Circ. J."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"8","DOI":"10.23736\/S0031-0808.18.03360-8","article-title":"High blood pressure, Alzheimer disease and antihypertensive treatment","volume":"60","author":"Marfany","year":"2018","journal-title":"Panminerva Med."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1007\/s40263-015-0230-6","article-title":"Antihypertensive drugs, prevention of cognitive decline and dementia: A systematic review of observational studies, randomized controlled trials and meta-analyses, with discussion of potential mechanisms","volume":"29","author":"Rouch","year":"2015","journal-title":"CNS Drugs"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1093\/ajh\/hpu197","article-title":"Neuroprotective effects of angiotensin receptor blockers","volume":"28","author":"Villapol","year":"2015","journal-title":"Am. J. Hypertens."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"e209788","DOI":"10.1212\/WNL.0000000000209788","article-title":"Hypertension, Antihypertensive Medications, and Dementia Risk in Old Age: A Complicated Relationship","volume":"103","author":"Yasar","year":"2024","journal-title":"Neurology"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1093\/brain\/awac076","article-title":"Blood-brain barrier permeable beta-blockers linked to lower risk of Alzheimer\u2019s disease in hypertension","volume":"146","author":"Beaman","year":"2023","journal-title":"Brain"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1161\/HYPERTENSIONAHA.121.17049","article-title":"Blood-Brain Barrier Crossing Renin-Angiotensin Drugs and Cognition in the Elderly: A Meta-Analysis","volume":"78","author":"Ho","year":"2021","journal-title":"Hypertension"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"2342","DOI":"10.4103\/1673-5374.336869","article-title":"Neuroinflammation as a mechanism linking hypertension with the increased risk of Alzheimer\u2019s disease","volume":"17","author":"Bajwa","year":"2022","journal-title":"Neural Regen. Res."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1093\/cvr\/cvac110","article-title":"Antihypertensive drugs and brain function: Mechanisms underlying therapeutically beneficial and harmful neuropsychiatric effects","volume":"119","author":"Carnovale","year":"2023","journal-title":"Cardiovasc. Res."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"6039171","DOI":"10.1155\/2018\/6039171","article-title":"The Role of Immunosenescence in Neurodegenerative Diseases","volume":"2018","author":"Costantini","year":"2018","journal-title":"Mediat. Inflamm."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"1398","DOI":"10.1038\/s41591-022-01822-2","article-title":"Performance of plasma phosphorylated tau 181 and 217 in the community","volume":"28","author":"Mielke","year":"2022","journal-title":"Nat. Med."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"2019","DOI":"10.1038\/s41467-025-57144-7","article-title":"Phosphorylated tau 181 and 217 are elevated in serum and muscle of patients with amyotrophic lateral sclerosis","volume":"16","author":"Scholle","year":"2025","journal-title":"Nat. Commun."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1093\/brain\/awae368","article-title":"Plasma p-tau217 in Alzheimer\u2019s disease: Lumipulse and ALZpath SIMOA head-to-head comparison","volume":"148","author":"Pilotto","year":"2024","journal-title":"Brain"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1001\/jamaneurol.2023.5319","article-title":"Diagnostic Accuracy of a Plasma Phosphorylated Tau 217 Immunoassay for Alzheimer Disease Pathology","volume":"81","author":"Ashton","year":"2024","journal-title":"JAMA Neurol."},{"key":"ref_44","doi-asserted-by":"crossref","unstructured":"Jones, F.K., Stefan, A., Kay, A.G., Hyland, M., Morgan, R., Forsyth, N.R., Pisconti, A., and Kehoe, O. (2020). Syndecan-3 regulates MSC adhesion, ERK and AKT signalling in vitro and its deletion enhances MSC efficacy in a model of inflammatory arthritis in vivo. Sci. Rep., 10.","DOI":"10.1038\/s41598-020-77514-z"},{"key":"ref_45","doi-asserted-by":"crossref","unstructured":"Sarrazin, S., Lamanna, W.C., and Esko, J.D. (2011). Heparan sulfate proteoglycans. Cold Spring Harb. Perspect. Biol., 3.","DOI":"10.1101\/cshperspect.a004952"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"C896","DOI":"10.1152\/ajpcell.00050.2022","article-title":"Coreceptor functions of cell surface heparan sulfate proteoglycans","volume":"322","author":"Hayashida","year":"2022","journal-title":"Am. J. Physiol. Cell Physiol."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1369\/0022155417742147","article-title":"Heparan Sulfate Proteoglycans as Relays of Neuroinflammation","volume":"66","author":"Zhang","year":"2018","journal-title":"J. Histochem. Cytochem."},{"key":"ref_48","doi-asserted-by":"crossref","unstructured":"Gopal, S., Arokiasamy, S., Pataki, C., Whiteford, J.R., and Couchman, J.R. (2021). Syndecan receptors: Pericellular regulators in development and inflammatory disease. Open Biol., 11.","DOI":"10.1098\/rsob.200377"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1016\/j.brainres.2019.05.031","article-title":"Sex differences in Alzheimer\u2019s disease: Understanding the molecular impact","volume":"1719","author":"Toro","year":"2019","journal-title":"Brain Res."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"4907","DOI":"10.1007\/s00018-021-03830-w","article-title":"Alzheimer\u2019s pathogenic mechanisms and underlying sex difference","volume":"78","author":"Zhu","year":"2021","journal-title":"Cell Mol. Life Sci."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"1208","DOI":"10.1016\/j.neuron.2024.01.024","article-title":"Mechanisms of sex differences in Alzheimer\u2019s disease","volume":"112","author":"Torres","year":"2024","journal-title":"Neuron"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.3758\/BRM.41.4.1149","article-title":"Statistical power analyses using G*Power 3.1: Tests for correlation and regression analyses","volume":"41","author":"Faul","year":"2009","journal-title":"Behav. Res. Methods"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"175","DOI":"10.3758\/BF03193146","article-title":"G*Power 3: A flexible statistical power analysis program for the social, behavioral, and biomedical sciences","volume":"39","author":"Faul","year":"2007","journal-title":"Behav. Res. Methods"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/j.jalz.2011.03.005","article-title":"The diagnosis of dementia due to Alzheimer\u2019s disease: Recommendations from the National Institute on Aging-Alzheimer\u2019s Association workgroups on diagnostic guidelines for Alzheimer\u2019s disease","volume":"7","author":"McKhann","year":"2011","journal-title":"Alzheimers Dement."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1016\/S1474-4422(14)70090-0","article-title":"Advancing research diagnostic criteria for Alzheimer\u2019s disease: The IWG-2 criteria","volume":"13","author":"Dubois","year":"2014","journal-title":"Lancet Neurol."}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/26\/14\/6587\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T18:07:12Z","timestamp":1760033232000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/26\/14\/6587"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,9]]},"references-count":55,"journal-issue":{"issue":"14","published-online":{"date-parts":[[2025,7]]}},"alternative-id":["ijms26146587"],"URL":"https:\/\/doi.org\/10.3390\/ijms26146587","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,9]]}}}